Corticosteroids, dopamine antagonists and other drugs

Herrstedt, Jørn; Aapro, Matti; Smyth, John F.; Favero, A. Del

doi:10.1007/s005200050155

Cited by 30 publications

(8 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, antiemetic guidelines [1–3] for MEC suggest the use of a 5-HT 3 RA and dexamethasone on day 1, followed by dexamethasone on days 2 and 3 to prevent delayed CINV. This recommendation stems from clinical evidence showing that corticosteroids increase the effect of other antiemetics [20] such as low-dose and high-dose metoclopramide [21], first generation 5-HT 3 RAs [22, 23], and a NK-1 receptor antagonist [24, 25]. Clinicians, however, have some concerns about the use of dexamethasone in clinical practice because of its potential side effects [5].…”

Section: Discussionmentioning

confidence: 99%

Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)

Renzo

Montanini

Mannina

et al. 2010

Support Care Cancer

View full text Add to dashboard Cite

PurposeThe control of nausea and vomiting induced by chemotherapy is paramount for overall treatment success in cancer patients. Antiemetic therapy during chemotherapy in lymphoma patients generally consists of anti-serotoninergic drugs and dexamethasone. The aim of this trial was to evaluate the efficacy of a single dose of palonosetron, a second-generation serotonin type 3 (5-HT3) receptor antagonist, in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy (MEC) containing steroids.MethodsPatients received a single intravenous bolus of palonosetron (0.25 mg) before administration of chemotherapy. Complete response (CR) defined as no vomiting and no rescue therapy during overall phase (0–120 h) was the primary endpoint. Complete control (CC) defined as CR and only mild nausea was a secondary endpoint.ResultsEighty-six evaluable patients entered in the study. A CR was observed in 74 patients (86.0%) during the overall phase; the CR during the acute (0–24 h) and delayed (24–120 h) phases was 90.7% and 88.4%, respectively. CC was 89.5% during the acute and 84.9% during the delayed phase; the overall CC was 82.6%.ConclusionsThis was the first trial, which demonstrated the efficacy of a single dose of palonosetron in control CINV in patients with aggressive non-Hodgkin’s lymphoma receiving MEC regimen containing steroids.

show abstract

Section: Discussionmentioning

confidence: 99%

Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)

Renzo

Montanini

Mannina

et al. 2010

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…An exception from this, is the effect of cannabinoids such as dronabinol, that is exerted by agonism of cannabinoid 1 (CB 1 ) receptors. The mechanism of action of corticosteroids is unknown, but hypotheses such as modification of the capillary permeability of the chemoreceptor trigger zone, decrease in the inflammatory changes in the gut and participation in the release of endorphins have been suggested [6].…”

Section: Pathophysiologymentioning

confidence: 99%

Anti‐Emetic Therapy in Cancer Chemotherapy: Current Status

Herrstedt

Dombernowsky

2007

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Nausea and vomiting are ranked as the most severe side effects to chemotherapy by cancer patients. Twenty years ago, treatment of nausea and vomiting from chemotherapy only had moderate effect and often unpleasant side effects. The drugs used included dopamine 2 -receptor antagonists and corticosteroids alone or combined. This review summarizes the development of anti-emetic therapy, but will focus on the importance of two new classes of anti-emetics: the serotonin 3 -and the neurokinin 1 -receptor antagonists. Furthermore, evidence-based guidelines for the treatment of chemotherapy-induced nausea and vomiting will be given. The serotonin 3 -receptor antagonists, the first group of drugs developed specifically as anti-emetics, have significantly improved the prophylaxis of chemotherapy-induced emesis especially in combination with a corticosteroid. The improvement in the prophylaxis of nausea with this combination is however modest. A new group of anti-emetics, the neurokinin 1 -receptor antagonists, has now been developed, and the first drug, aprepitant, was marketed in 2003. Aprepitant increases the effect of a serotonin 3 -receptor antagonist plus a corticosteroid against acute emesis induced by highly or moderately emetogenic chemotherapy and aprepitant is also active in the protection against delayed emesis. The importance of drug-drug interactions with anti-emetics and other drugs, especially cytotoxins, through their competition for cytochrome P450 enzymes, have been studied. At present, there is no evidence that such interactions are of major clinical importance. Evidence-based clinical guidelines are now available and regularly updated, but unfortunately clinical implementation is slow. Recommendations for some types of chemotherapyinduced emesis such as delayed emesis, is based on a low level of evidence. Furthermore, the majority of clinical trials include highly selected groups of patients not permitting definite conclusions for other and more heterogeneous patient groups. Development of new anti-emetics with other mechanisms of action is awaited with interest.

show abstract

“…Considerable progress has been made in the pharmacological management of CINV and numerous studies have provided evidence on the efficacy of anti‐emetic therapies alone and in combination. While corticosteroids and dopamine antagonists have long been used in the treatment of acute emesis, the emergence of the selective serotonin (5‐HT 3 ) receptor antagonists in combination with dexamathasone has improved effectiveness and diminished treatment‐related toxicity (Herrstedt et al . 1997).…”

Section: Introductionmentioning

confidence: 99%

Hypnosis for nausea and vomiting in cancer chemotherapy: a systematic review of the research evidence

et al. 2007

View full text Add to dashboard Cite

To systematically review the research evidence on the effectiveness of hypnosis for cancer chemotherapy-induced nausea and vomiting (CINV). A comprehensive search of major biomedical databases including MEDLINE, EMBASE, ClNAHL, PsycINFO and the Cochrane Library was conducted. Specialist complementary and alternative medicine databases were searched and efforts were made to identify unpublished and ongoing research. Citations were included from the databases' inception to March 2005. Randomized controlled trials (RCTs) were appraised and meta-analysis undertaken. Clinical commentaries were obtained. Six RCTs evaluating the effectiveness of hypnosis in CINV were found. In five of these studies the participants were children. Studies report positive results including statistically significant reductions in anticipatory and CINV. Meta-analysis revealed a large effect size of hypnotic treatment when compared with treatment as usual, and the effect was at least as large as that of cognitive-behavioural therapy. Meta-analysis has demonstrated that hypnosis could be a clinically valuable intervention for anticipatory and CINV in children with cancer. Further research into the effectiveness, acceptance and feasibility of hypnosis in CINV, particularly in adults, is suggested. Future studies should assess suggestibility and provide full details of the hypnotic intervention.

show abstract

Corticosteroids, dopamine antagonists and other drugs

Cited by 30 publications

References 93 publications

Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)

Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)

Anti‐Emetic Therapy in Cancer Chemotherapy: Current Status

Hypnosis for nausea and vomiting in cancer chemotherapy: a systematic review of the research evidence

Contact Info

Product

Resources

About